SCHEMBL3736889

SCHEMBL3736889

O=C1NCC2C3CCC(O3)C12

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.46
▸ GMNN O75496 1/20 0.46
▸ PPM1B O75688 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PPP1CC P36873 1/20 0.46
▸ TFPI2 P48307 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ PPP5C P53041 1/20 0.46
▸ PPP1CA P62136 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ NFKB1 P19838 1/20 0.46
▸ THPO P40225 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3748183 0.70 MEN1 (0.33) —
SCHEMBL17773447 0.69 TP53 (0.56) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL14381277 0.69 TP53 (0.56) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL2548229 0.69 TP53 (0.56) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL13311452 0.69 TP53 (0.56) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL11931883 0.67 ATM (0.38) —
SCHEMBL3738829 0.67 ATM (0.38) —
SCHEMBL19911091 0.67 PPM1B (0.48) KDM4EGMNNPPM1BLMNAPPP1CC
SCHEMBL3735337 0.67 ALDH1A1 (0.36) KDM4ELMNAL3MBTL1
SCHEMBL9468271 0.65 KDM4E (0.52) KDM4EGMNNPPM1BLMNAPPP1CC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242285-B2 N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 — — US disclosed
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 — — US disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 — — US disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 KDM4E 424/4885GMNN 2598/4885PPM1B 2994/4885
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof TERT, CBR1, TELO2 KDM4E 424/4885GMNN 2598/4885PPM1B 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback